NCT06547840View on ClinicalTrials.gov

A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

March 31, 2027

Conditions
Advanced Ovarian CancerPlatinum-resistant Ovarian Cancer
Interventions
DRUG

MOv18 IgE

MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class

Trial Locations (7)

BS2 8ED

RECRUITING

Bristol Haematology and Oncology Centre, Bristol

EH4 2XR

RECRUITING

Edinburgh Cancer Research Centre, Edinburgh

LS9 7LP

RECRUITING

Leeds Teaching Hospitals NHS Trust, Leeds

CB2 0QQ

RECRUITING

Cambridge University - Addenbrooke's Hospital, London

NW1 2BU

RECRUITING

University College London Hospital, London

SE1 3SS

RECRUITING

Guy's Hospital, London

SO16 6HU

RECRUITING

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors

Lead Sponsor

Epsilogen Ltd
All Listed Sponsors
lead

Epsilogen Ltd

INDUSTRY

NCT06547840 - A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer | Biotech Hunter | Biotech Hunter